BetaGlue Therapeutics

Executive Summary

BetaGlue Therapeutics is an Italian biotech company pioneering targeted nuclear therapies for solid tumors, with a lead program focused on pancreatic cancer. Founded in 2015 and headquartered in Milan, the company leverages its proprietary YntraDose technology platform to deliver radiotherapy directly and locally to tumors, aiming to improve efficacy and reduce off-target toxicity. Currently in Phase 1 clinical development, BetaGlue is evaluating its lead radiotherapeutic candidate in patients with advanced pancreatic cancer. The company's approach addresses a high unmet need, as pancreatic cancer remains one of the most lethal malignancies with limited treatment options. BetaGlue's platform has the potential to be expanded to other solid tumor indications. Despite being in early clinical stages, the company's innovative technology and focus on localized radiotherapy position it as a noteworthy player in the radiopharmaceutical space. Key upcoming milestones include initial safety and efficacy data from its ongoing Phase 1 trial, which could provide proof-of-concept for the YntraDose platform.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim safety and efficacy data readout55% success
• TBDPotential partnering or licensing deal for YntraDose platform40% success
• Q2 2026Regulatory update for Phase 1 trial expansion into additional solid tumors70% success